<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674739</url>
  </required_header>
  <id_info>
    <org_study_id>GW01-0801</org_study_id>
    <nct_id>NCT00674739</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graceway Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Graceway Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether imiquimod creams are effective in treating
      external genital warts (EGW). The secondary objective of this study is to provide information
      on recurrence of EGW. Additionally the study will also look at any adverse events associated
      with the use of the creams.

      External genital and perianal warts are caused by the infection of human papillomavirus or
      HPV. HPV infection is a sexually transmitted disease (STD). External genital warts look like
      small flesh-colored, pink, or red growths on or around the external skin of sex organs or
      perianal area. The warts may look similar to the small parts of a cauliflower or they may be
      very tiny and difficult to see. They often appear in clusters of three or four, and may grow
      and spread rapidly. They usually are not painful, although they may cause mild pain,
      bleeding, and itching.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Proportion of subjects with complete clearance of all warts (both presented at Baseline and newly emerged warts) at End of Study. Primary analysis performed on the Intent to Treat population with imputation (Last Observation Carried Forward)for missing data points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Variables Include Adverse Reactions (AEs), Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period.</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Local skin reactions in the treatment and/or immediate surrounding area were clinically identified as: erythema, edema, weeping/exudate, flaking/scaling/dryness, and erosion/ulceration. LSRs were visually assessed by investigator at each visit.
Rest period was a temporary interruption of dosing dur to intolerable LSRs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Adverse Events</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Numbers of subjects in each treatment group reporting one or more adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">470</enrollment>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>imiquimod cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5% imiquimod cream applied daily to wart area for up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.75% imiquimod cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo cream applied daily to wart areas for up to 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>daily topical application for up to 8 weeks</description>
    <arm_group_label>imiquimod cream</arm_group_label>
    <other_name>imiquimod 2.5% topical creram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3.75% imiquimod cream</intervention_name>
    <description>3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.</description>
    <arm_group_label>3.75% imiquimod cream</arm_group_label>
    <other_name>3.75% imiquimod topical cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo cream</intervention_name>
    <description>placebo cream applied daily to wart areas for up to 8 weeks</description>
    <arm_group_label>placebo cream</arm_group_label>
    <other_name>placebo matching cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good general health

          -  Diagnosis of external genital / perianal warts with at least 2 warts and no more than
             30 warts

          -  Negative pregnancy test (for women who are able to become pregnant)

        Exclusion Criteria:

          -  Women who are pregnant, lactating or planning to become pregnant during the study

          -  Evidence of clinically significant or unstable disease (such as stroke, heart attack)

          -  Have any of the following conditions: HIV infection; current or history of high risk
             HPV infection (e.g., HPV 16, 18, etc.); outbreak of herpes genitalia in the wart
             areas; internal warts requiring or undergoing treatment; dermatological disease (e.g.,
             psoriasis) or skin condition in the wart areas

          -  Have received specific treatments in the treatment area(s) within the designated time
             period prior to study treatment initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Wu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Graceway Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WILMAX Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery Women's Health Associates</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Pharmaceutical Research</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinger Medical Group Clinical Research Center</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Dermatology Medical Group</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Medical Research Group</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicos, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perimeter Institute for Clinical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta North Gynecology</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Infectious Disease Research Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Practice</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health Clinic</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Purchase</city>
        <state>New York</state>
        <zip>10577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of NY Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Institute of Dermatology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Quality Research, Women Partners in Health</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Quality Research, The Urology Team</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Dermatology Dept</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <results_first_submitted>April 24, 2011</results_first_submitted>
  <results_first_submitted_qc>April 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2011</results_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jason Wu, MD / Exective Director, Product Development</name_title>
    <organization>Graceway Pharmaceuticals, LLC</organization>
  </responsible_party>
  <keyword>external genital warts</keyword>
  <keyword>perianal warts</keyword>
  <keyword>condylomata acuminata</keyword>
  <keyword>venereal warts</keyword>
  <keyword>HPV types 6 and 11</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period from June to December 2008 from 30 clinical study centers in the USA</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2.5% Imiquimod Cream</title>
          <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>3.75% Imiquimod Cream</title>
          <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2.5% Imiquimod Cream</title>
          <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>3.75% Imiquimod Cream</title>
          <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="178"/>
            <count group_id="B2" value="195"/>
            <count group_id="B3" value="97"/>
            <count group_id="B4" value="470"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="11.3"/>
                    <measurement group_id="B2" value="32.5" spread="11.6"/>
                    <measurement group_id="B3" value="30.5" spread="10.6"/>
                    <measurement group_id="B4" value="32.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Safety Variables Include Adverse Reactions (AEs), Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period.</title>
        <description>Local skin reactions in the treatment and/or immediate surrounding area were clinically identified as: erythema, edema, weeping/exudate, flaking/scaling/dryness, and erosion/ulceration. LSRs were visually assessed by investigator at each visit.
Rest period was a temporary interruption of dosing dur to intolerable LSRs.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2.5% Imiquimod Cream</title>
            <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>3.75% Imiquimod Cream</title>
            <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Variables Include Adverse Reactions (AEs), Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period.</title>
          <description>Local skin reactions in the treatment and/or immediate surrounding area were clinically identified as: erythema, edema, weeping/exudate, flaking/scaling/dryness, and erosion/ulceration. LSRs were visually assessed by investigator at each visit.
Rest period was a temporary interruption of dosing dur to intolerable LSRs.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Skin Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with Rest Period in Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study</title>
        <description>Proportion of subjects with complete clearance of all warts (both presented at Baseline and newly emerged warts) at End of Study. Primary analysis performed on the Intent to Treat population with imputation (Last Observation Carried Forward)for missing data points.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>2.5% Imiquimod Cream</title>
            <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>3.75% Imiquimod Cream</title>
            <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study</title>
          <description>Proportion of subjects with complete clearance of all warts (both presented at Baseline and newly emerged warts) at End of Study. Primary analysis performed on the Intent to Treat population with imputation (Last Observation Carried Forward)for missing data points.</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.191" lower_limit="0.136" upper_limit="0.257"/>
                    <measurement group_id="O2" value="0.272" lower_limit="0.211" upper_limit="0.340"/>
                    <measurement group_id="O3" value="0.103" lower_limit="0.051" upper_limit="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Related Adverse Events</title>
        <description>Numbers of subjects in each treatment group reporting one or more adverse events</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Patients with adverse events considered probably related or related to the administration of the product.</population>
        <group_list>
          <group group_id="O1">
            <title>2.5% Imiquimod Cream</title>
            <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>3.75% Imiquimod Cream</title>
            <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cream applied once daily to wart areas for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Adverse Events</title>
          <description>Numbers of subjects in each treatment group reporting one or more adverse events</description>
          <population>Patients with adverse events considered probably related or related to the administration of the product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year</time_frame>
      <desc>The study duration included 5 month enrollment period, up to 28 week of study period, so total duration from first patient enrolled to the last patient completed study was approximately 12 months</desc>
      <group_list>
        <group group_id="E1">
          <title>2.5% Imiquimod Cream</title>
          <description>2.5% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>3.75% Imiquimod Cream</title>
          <description>3.75% imiquimod cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo cream applied once daily to wart areas for up to 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <description>Worsened iron deficiency anemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <description>Acute Surgical Abdomen</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>Cholecystolithiasis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <description>Worsening migraine headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Syncope</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For few PIs, there were a restrict that the PI can not publish their trial results with 12 months from the completion of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Babilon, Vice President, Product Development</name_or_title>
      <organization>Graceway Pharmaceuticals</organization>
      <phone>267-948-0400 ext 20428</phone>
      <email>robert.babilon@gracewaypharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

